Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
CA 2289454 A1 · Owner: Isis Pharmaceuticals Inc. · Inventors: Sanghvi, Yogesh S.; Cook, Phillip Dan; Freier, Susan M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compositions and methods are provided for the modulation of expression of the human ras gene in both the normal and activated forms. Oligonucleotides are provided that have methylene(methylimino) linkages alternating with phosphorothioate or phosphodiester linkages. Further oligonucleotides are provided that have a first region having a methylene(methylimino) linkage alternating with a phosphorothioate or phosphodiester linkage and a second region having phosphorothioate linkages. Such oligonucleotides can be used for diagnostics as well as for research purposes including methods for diagnosis detection and treatment of conditions arising from the activation of the H-ras gene.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 30, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 30, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 30, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.